

|
... e forms of vitamin D cost more than standard supplemental vitamin D and are associated with increased risk for hypercalcemia -- elevated calcium levels in the blood. The U.S. National Institute on Aging has more about falls and older adults .
|
|
... option for advanced breast cancer patients." Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa (hazard ratio 0.82, 95 percent CI: 0.70, 0.95; p=0.007). The median time to first ...
|
|
... statistically significant for non-inferiority. Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa. The median time to first on-study SRE or HCM was 19 months for denosumab versus 14.4 ...
|
|
... option for advanced breast cancer patients." Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa (hazard ratio 0.82, 95 percent CI: 0.70, 0.95; p=0.007). The median time to first ...
|
|
... first on-study SRE was 26.5 months for Zometa. Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy compared with Zometa. In a
|
|
... option for advanced breast cancer patients." Denosumab also delayed the median time to first on-study SRE or hypercalcemia of malignancy (HCM) compared to Zometa (hazard ratio 0.82, 95 percent CI: 0.70, 0.95;> Bone pain can dominate the daily lives ...
|
|
... * Obstructive uropathy (chronic urinary obstruction such as due to prostatic disease or metastatic cancer) * Hypercalcemia (chronically elevated blood calcium levels) Step 2 If you are experiencing any of the following signs and symptoms, discuss ...
|
|
... invasive parathyroid surgery during pregnancy. We report the clinical course of two pregnant women with severe hypercalcemia due to primary hyperparathyroidism, as well as review the literature. Results: Primary hyperparathyroidism in pregnant women ...
|